Norstella completed its acquisition of clinical trial intelligence specialist Citeline as part of the pharma solutions group’s goal to become a global leader in end-to-end consultancy services for the industry.
Although financial terms weren’t disclosed, Norstella estimates that it is now a $5 billion player in the market, the company said in a Nov. 1 press release. The acquisition was first announced in June.
Citeline, which was formerly known as Pharma Intelligence, joins Norstella’s other four constituent groups: pharma commercial intelligence provider Evaluate, market access specialist MMIT, healthcare data analytics software provider Panalgo and market access consultancy The Dedham Group.
"As the industry moves toward highly targeted therapies focused on smaller patient populations, our clients need solutions that provide actionable answers to critical business questions to help bring drugs to market quicker—ultimately helping patients receive treatment sooner,” Norstella CEO Mike Gallup said in a release.
Norstella, which, following the acquisition, now boasts more than 1,600 employees, said it is focused on developing solutions for clients that can help them identify unmet clinical needs earlier, design clinical trials with endpoints that support reimbursement decisions and identify eligible patients for trials.